Search research articles
Contact Us
Filters
Showing results (1-10 of 66) with videos related to
Page
of 7
Sort By:
European Urology
|
October 28, 2008
Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis
Aristotle Bamias
European Urology
|
March 21, 2007
Editorial comment on: Impact of multimodal treatment on survival in patients with metastatic urothelial cancer
Aristotle Bamias
Current Cancer Drug Targets
|
August 12, 2008
Targeting angiogenesis in renal cell carcinoma
Georgios Lainakis, Aristotle Bamias
Translational Andrology and Urology
|
January 29, 2019
Treating bladder adenocarcinoma
Georgios Tsironis, Aristotle Bamias
Expert Opinion on Investigational Drugs
|
February 16, 2005
Thalidomide and immunomodulatory drugs in the treatment of cancer
Aristotle Bamias, Meletios A Dimopoulos
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese
|
March 15, 2006
Inhibition of angiogenesis: common theme for cancer and atheromatosis?
Aristotle Bamias, Meletios A Dimopoulos
Expert Review of Anticancer Therapy
|
December 13, 2005
Neoadjuvant chemotherapy in invasive bladder cancer
Aristotle Bamias, Meletios A Dimopoulos
European Journal of Internal Medicine
|
February 14, 2004
Angiogenesis in human cancer: implications in cancer therapy
Aristotle Bamias, Meletios A. Dimopoulos
Therapeutic Advances in Medical Oncology
|
November 29, 2023
Current role of PSMA-PET imaging in the clinical management of prostate cancer
Alexander Georgakopoulos, Aristotle Bamias, Sophia Chatziioannou
Expert Review of Anticancer Therapy
|
June 29, 2011
Management of advanced bladder cancer in patients with impaired renal function
Evangelos Bournakis, Meletios A Dimopoulos, Aristotle Bamias
Page
of 7
Search research articles
Search
Showing results (1-10 of 66) with videos related to
Sort By:
Page
of 7
European Urology
|
October 28, 2008
Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis
Aristotle Bamias
European Urology
|
March 21, 2007
Editorial comment on: Impact of multimodal treatment on survival in patients with metastatic urothelial cancer
Aristotle Bamias
Current Cancer Drug Targets
|
August 12, 2008
Targeting angiogenesis in renal cell carcinoma
Georgios Lainakis, Aristotle Bamias
Translational Andrology and Urology
|
January 29, 2019
Treating bladder adenocarcinoma
Georgios Tsironis, Aristotle Bamias
Expert Opinion on Investigational Drugs
|
February 16, 2005
Thalidomide and immunomodulatory drugs in the treatment of cancer
Aristotle Bamias, Meletios A Dimopoulos
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese
|
March 15, 2006
Inhibition of angiogenesis: common theme for cancer and atheromatosis?
Aristotle Bamias, Meletios A Dimopoulos
Expert Review of Anticancer Therapy
|
December 13, 2005
Neoadjuvant chemotherapy in invasive bladder cancer
Aristotle Bamias, Meletios A Dimopoulos
European Journal of Internal Medicine
|
February 14, 2004
Angiogenesis in human cancer: implications in cancer therapy
Aristotle Bamias, Meletios A. Dimopoulos
Therapeutic Advances in Medical Oncology
|
November 29, 2023
Current role of PSMA-PET imaging in the clinical management of prostate cancer
Alexander Georgakopoulos, Aristotle Bamias, Sophia Chatziioannou
Expert Review of Anticancer Therapy
|
June 29, 2011
Management of advanced bladder cancer in patients with impaired renal function
Evangelos Bournakis, Meletios A Dimopoulos, Aristotle Bamias
Page
of 7